The strategy of using biologically targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood–brain barrier on the ability of a therapeutic to reach its target(s). Clin Cancer Res; 24(16); 3790–1. ©2018 AACR.
See related article by Sanai et al., p. 3820
https://ift.tt/2nDQkNR
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.